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Tumor-to-tumor metastasis is a fairly rare phenomenon. The lung cancers are the most common donors, but are
exceedingly rare as recipients. Here we report a case of a lung adenocarcinoma acting as the recipient of papillary
thyroid carcinoma, with multiple spreading foci of the two cancers in the lung simultaneously. The morphology
and immunohistochemisty (Napsin-A, Thyroglobulin) are very important in differential diagnosis of lung primary
adenocarcinoma and metastatic papillary thyroid carcinoma.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2069496615891134
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Coexistence of two or more primary neoplasms in one
patient is not uncommon, however, tumor-to-tumor
metastasis is a fairly uncommon but interesting phe-
nomenon. The most frequent recipient is renal clear
cell carcinoma, followed by sarcoma, meningioma, and
thyroid neoplasm, while the most common donor is
lung carcinoma, followed by carcinoma of the breast,
gastrointestinal tract, prostate, and thyroid [1,2]. The
lung cancers are the most common donors, but are ex-
ceedingly rare as recipients. To date, only 3 cases of
lung cancer acting as the recipient of papillary thyroid
carcinoma were reported in English-language literature.
They were invasive adenocarcinoma, squamous cell car-
cinoma, and non-mucinous adenocarcinoma in situ, re-
spectively [3-5]. Here we report a case that papillary
thyroid carcinoma metastasized into a lung primary in-
vasive adenocarcinoma, with multiple spreading foci of
the two cancers in the lung simultaneously.* Correspondence: nlu03@126.com; lindm3@163.com
†Equal contributors
1Department of Pathology, Cancer Institute (Hospital), Peking Union Medical
College, Chinese Academy of Medical Sciences, Beijing, China
Full list of author information is available at the end of the article
© 2013 Xue et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
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A 65-year-old Chinese man underwent total thyroidectomy
and bilateral neck dissection with 131I treatment after
that for papillary thryoid cancer in a local hospital. The
papillary thryoid cancer extended to perithyroid soft
tissues (pT3) with bilateral neck lymph node metastasis
(pN1b). Chest Computed Tomography (CT) scan was
not performed that time. Seven months later, a mass in
his lung was found without any symptoms in physical
examination.Immunohistochemistry
Specimens were fixed in 10% buffered formalin, embedded
in paraffin and stained with HE method routinely for
histological examination. Immunohistochemical staining
was performed using an automated immunostainer
(Ventana Benchmark XT; Ventana Medical Systems, Inc,
Tucson, AZ). Antibodies against Cytokeratin 19 (CK19),
Cytokeratin 7 (CK7), Napsin-A, Thyroglobulin and Thy-
roid Transcription Factor-1 working solution (CK19 and
CK7: Zhong Shan –Golden Bridge Biological Technology
Co. Ltd., Beijing, China; Napsin-A and Thyroid Transcrip-
tion Factor-1: Maxim Biological Techology Co. Ltd.,
Fuzhou, China; Thyroglobulin: Dako Corp, Carpinteria,
CA, USA). Antigen recovery was conducted using
moderate heat retrieval according to manufacturer’s. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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antibody for 30 mininutes at room temperature.
Results
PET-CT and CT revealed a large lobular mass in the su-
perior lobe of left lung. The largest dimension of the
mass is 3.2 cm. It invaded the anterior segment and su-
perior segment of the left lung, and invaded pleura
mediastinalis. The imaging of the rest lung looks normal
(Figure 1). Many lymph nodes can be seen in the 2R, 4R,
4 L, 5 and 6 regions of mediastina, with the maximum
dimension is 1.4 cm. According to the recommendation
of PET-CT and CT examination, the patient underwent
lobectomy. The patient was alive half a year later.
Gross examination showed a tumor in the periphery of
the lung, measuring 3.5 × 3.5 × 2.5 cm. The cut section
surface of the tumor was hard, grey and fine granular.
There were many small grey nodes in the rest lung and
pleura, with a diameter of 0.1 cm to 0.3 cm. There were
plenty of small nodes on the visceral pleura (Figure 1).
Microscopically, two different cell populations were
identified. They were mixed with each other. One was
with typical papillary thyroid carcinoma morphology
with typical papillary pattern, ground glass nuclei,
groove and colloid. The other was with primary lung
adenocarcinoma morphology, mainly consisted of acinar
pattern. Micro-papillary and leptic (bronchioloalveolar
carcinoma) patterns can also be seen. Cytoplasm wasc
db
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Figure 1 PET-CT imaging features and macroscopic features. CT revea
dimension of the mass is 3.2 cm. It invaded the anterior segment and supe
imaging of the rest lung looks normal (a). PET and CT fusion image showe
suggested a malignant tumor on PET-CT, and probably lung primary cance
lung, with the largest diameter of 3.5 cm. The cut section surface of the tu
nodes (arrows) in the rest lung, with a diameter of 0.1 cm to 0.3 cm (c). Thabundant and acidophilia. Nuclei were dark stained, with
small nucleoli and evenly distributed chromatin. In the
surrounding lung, the two tumor components, meta-
static papillary thyroid carcinoma and lung adenocarcin-
oma, spread as small foci simultaneously. They were also
mixed with each other. The spreading lung adenocarcin-
oma was mainly acinar pattern and micro-papillary
pattern but not leptic pattern or adenoid atypical hyper-
plasia (AAH) (Figures 2 and 3). Metastatic carcinoma in
the lymph nodes was lung adenocarcinoma. CK7, CK19
and Thyroid Transcription Factor-1 were positive in
both cell populations. Napsin A was positive in primary
lung adenocarcinoma, but negative in metastatic papil-
lary thyroid carcinoma. Thyroglobulin was positive in
metastatic papillary thyroid carcinoma, but negative in
primary lung adenocarcinoma (Figure 4).
Discussion
Very few reports of tumor-to-tumor metastasis are
present in the English literature. The terms “tumor-to
-tumor metastasis” and “collision tumor” have often been
confused with one another, and used incorrectly in the lit-
erature. Collision tumor is defined as two neighboring
neoplasms that invade one another. Tumor-to-tumor me-
tastasis has proved more difficult to be defined, with sev-
eral proposed similar criteria in order to be classified
correctly. The criteria of Campbell et al. to define tumor-
to-tumor metastasis are as follows [2]. (1) more than oneled a large lobular mass in the superior lobe of left lung. The largest
rior segment of the left lung, and invaded pleura mediastinalis. The
d the nodule had intense FDG uptake. The SUVmaxs was 5.2, which
r (b). Gross examination showed a tumor (▲) in the peripheral of the
mor was hard, grey and fine granular, and there were many small grey
ere were plenty of small nodes (arrows) on the visceral pleura (d).
Figure 2 Microscopic features of the metastatic papillary thyroid carcinoma and primary lung adenocarcinoma. Metastatic papillary




Figure 3 Microscopic features of the metastatic papillary thyroid carcinoma and primary lung adenocarcinoma. The typical papillary
pattern, ground glass nuclei, groove and colloid were found in metastatic papillary thyroid carcinoma (a, b). The tumor was mainly consisted of
acinar pattern in primary lung adenocarcinoma. Micro-papillary and leptic (bronchioloalveolar carcinoma) patterns can also be seen (c, d, e, f). In
the other area of the lung, the two tumor components, metastatic papillary thyroid carcinoma (→) and lung adenocarcinoma (▲), spread
simultaneously. They were mixed with each other (g, h). Metastatic carcinoma in the lymph nodes was lung adenocarcinoma (i).






Figure 4 Immunohistochemical features of the metastatic papillary thyroid carcinoma and primary lung adenocarcinoma. Napsin A was
positive in primary lung adenocarcinoma (▲), but negative in metastatic papillary thyroid carcinoma (→) (a, b and c). Thyroglobulin was positive
in metastatic papillary thyroid carcinoma (→), but negative in primary lung adenocarcinoma (▲) (d, e and f).
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benign or malignant neoplasm; (3) the metastatic neo-
plasm is a true metastasis with established growth in the
host tumor, not the result of contiguous growth (collision
tumor) or embolization of tumor cells; (4) involvement by
metastatic tumors of lymph nodes already involved by
lymphoproliferative disease (lymphoreticular malignant
tumors) is excluded. According to the literature, renal
clear cell carcinoma is the most common tumor recipient
of metastasis while lung carcinoma is the most common
donor tumor [1,2,6]. Tumor-to-tumor metastasis is not as
infrequent as previously thought and may be present in
up to 15 percent of patients with simultaneous renal clear
cell carcinoma and second neoplastic disease [6]. Com-
monly, the donor tumor is an aggressive malignant tumor.
On the other hand, the recipient tumor is usually a low-
grade malignancy or benign neoplasm. It is extremely rare
that an aggressive malignant tumor as the recipient tumor
while a low-grade malignancy as the donor tumor. Only
three cases of papillary thyroid carcinoma, a low-grade
malignancy, metastasizing to a lung cancer, an aggressive
malignant tumor, were reported [3-5]. There were more
reports about lung cancer metastasizing to a thyroid
tumor [7-10].
The tumor cells (forming the ‘seed’) are hematogenously
disseminated in a widespread manner to different anatomic
sites, but attain successful growth and propagation only
under the favorable local microenvironments of specific
organs or the recipient tumors (the ‘soil’). Renal clear cell
carcinoma is the most common recipient tumor in tumor-
to-tumor metastasis. This might be attributable to its
increased vascularity. Biochemical properties of renal cellcarcinoma, such as increased cytoplasmic lipid and glyco-
gen of constituent cells, has also been proposed as contrib-
uting to this tumor being a favorable site for metastatic
growth [11]. The lung is one of the most frequent sites of
metastasis for the extrathoracic cancers. However, lung car-
cinoma is one of the rarest recipients for tumor-to-tumor
metastasis. Presence of different vascular structures be-
tween normal lung and lung cancer may be the possible
reason for the different potential as a site of metastasis. Un-
like normal lung, lung cancer doesn’t contain a rich net-
work of small thin-walled blood vessels. The other possible
explanation which we considered was that lung cancer is
rapidly growing tumor therefore it cannot provide a
suitable environment for the acceptance of metastasis.
Regarding the reason for the relatively high incidence of
lung cancer as a donor in tumor-to-tumor metastasis, the
rich vascularity of lung carcinoma in association with the
probable shedding of tumor cells during respiratory move-
ment might increase the frequency of invasion into the pul-
monary vein and subsequently into the general circulation.
The tumor emboli from lung cancer have a better chance
to reach all the body organs through the left-sided cardiac
output than cancers of the other organs.
It is still unexplained whether tumor-to-tumor metas-
tasis is merely of a chance occurrence or is a selective
growth within the recipient tumor. In our case, a lung
mass with metastatic papillary thyroid carcinoma was
the first metastatic focus discovered during the post-
operative follow-up of this patient. Our case showed that
the metastatic papillary thyroid adenocarcinoma foci
were not limited to the primary lung adenocarcinoma
and multiple microscopic foci of thyroid papillary foci
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Multi foci of metastases can also be seen both within the
lung cancer and in the background lung tissue in the 3
reported cases of a lung cancer acting as the recipient of
a donor of papillary thyroid carcinoma [3-5]. In addition,
multiple spreading small lung adenocarcinoma can also
be seen in the background lung tissue in our present
case while the 3 reported cases didn’t show this. Papil-
lary thyroid carcinoma is a slowly growing tumor.
Disease-specific survival with distant metastases at 5 and
10 years was reported to be 65 and 45%, respectively
[12]. The metastatic foci of papillary thyroid carcinoma
had probably already been there before lung primary
adenocarcinoma occurred, and the metastases to lung
cancer had occurred by chance.
The presence of a lung mass in a patient with a prior
cancer can represent a clinically and/or pathologically
diagnostic challenge. Some of these lung masses repre-
sent primary processes rather than metastatic deposits.
The diagnosis of metastatic carcinoma to the lung by
core biopsy, frozen section, and permanent sections can
be easily misinterpreted as a primary tumor. The possi-
bility of metastatic papillary thyroid carcinoma should
always be considered when two different cell populations
are identified, and specifically, one should be aware of in
the presence of papillary component in a lung carcin-
oma. The diagnosis of metastatic papillary thyroid car-
cinoma mainly depends on the morphology of the
nucleus and immunohistochemical expression. The pap-
illary thyroid carcinoma is composed of cells with
ground glass nuclei in the cells and colloid in the thyroid
follicles, which are the important characteristics different
from other carcinomas. Lepdic or adenocarcinoma in
situ components in the surgical specimens can also help
to differentiate primary lung adenocarinoma from other
carcinomas. Thyroid Transcription Factor-1 is one of
the immunohistochemical markers most commonly used
to assist in the differential diagnosis of carcinomas of
the lung and thyroid from other carcinomas. But it can-
not differentiate between lung carcinoma and thyroid
carcinoma. CK19, galectin-3 (Gal-3) and Hector Battifora
mesothelial-1 (HBME-1) have been studied to distinguish
between malignant and benign lesions of the thyroid
gland. The diagnostic efficiency of CK19 for papillary thy-
roid carcinoma was slightly better than that of Gal-3 and
HBME-1. The utilization of these markers combined with
morphologic evaluation may be helpful in the differential
diagnosis of papillary thyroid carcinoma and benign
lesions [13,14]. But they cannot distinguish metastatic
papillary thyroid carcinoma from lung adenocarcinoma.
Thyroglobulin is an antibody specially expressed in nor-
mal thyroid and thyroid carcinoma, which we can use in
the differential diagnosis of lung carcinoma and thyroid
carcinoma. Napsin A is an aspartic proteinase involved inthe maturation of surfactant protein B. It is detected in
the cytoplasm of type 2 pneumocytes and alveolar
macrophages and is a putative marker for lung adenocar-
cinomas. It can also help to differentiate lung adenocar-
cinoma from metastatic papillary thyroid carcinoma [15].
Recently, microarray based gene expression profiling has
found increasing use, particularly in the most difficult
cases. Gene expression profiling provides correct primary
site identification in a higher percentage, of metastatic
cases than immnunohistochemistry-guided methods (90%
vs. 64%), and uses less tissue [16]. In our present case,
the morphology and immunohistochemical expression
of the two components were typical. It was a rare case,
but not difficult for pathologist, so gene expression pro-
filing is not necessary.
Conclusion
In summary, when there is a tumor in the lung of a pa-
tient with papillary thyroid carcinoma history, tumor-to
-tumor metastasis should be considered. Such a tumor-
to-tumor metastasis should be differentiated from primary
mixed adenocarcinoma, which is composed of papillary
adenocarcinoma and other subtypes of adenocarcinoma of
lung. Tumor-to-tumor metastasis may become more
frequent because of the improving prognosis and survival
of patients with malignancies. Awareness about this
phenomenon of tumor-to-tumor metastasis, careful exam-
ination of morphology and proper immunohistochemical
staining such as Thyroglobulin and Napsin A are import-
ant for correct diagnosis and appropriate therapy.
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